secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0000950170-23-004639
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte reports Q4 2022 net loss of $78.1M; cash $957.9M; VAX-24 infant IND cleared
--------------------------------------------------------------------------------

- Net loss of $78.1M for Q4 2022 and $223.5M for full year 2022; R&D expenses $51.6M and $169.5M respectively.
- Cash, cash equivalents and investments $957.9M as of Dec 31, 2022, up from $273.1M a year ago.
- FDA cleared VAX-24 infant IND; Phase 2 infant study to start Q2 2023; Breakthrough Therapy designation for adults.
- Positive Phase 1/2 data for VAX-24 in adults 18-64; Phase 2 study in adults 65+ enrollment completed; topline data expected Q2 2023.
- Raised ~$805M in gross proceeds from two follow-on equity offerings in 2022; VAX-31 adult IND expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000095017023004639/0000950170-23-004639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000095017023004639/pcvx-20230227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-004639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer